Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 mild to moderate meta-analysis

Rashad A_AZI vs SoC, 2021 RCTazithromycinstandard of careCOVID-19 mild to moderatesome concern
107/99 inconclusive
    COALITION I Covid-19 Brazil _AZI (Cavalcanti), 2020
     
    NCT04322123
    RCTazithromycinstandard of careCOVID-19 mild to moderatesome concern
    172/159 inconclusive
    • inconclusive 18 % decrease in clinical improvement,clinical improvement (14-day) (PE) with a moderate degree of certainty due to some concern in risk of bias
    Espitia-Hernandez, 2020 NRaazithromycinstandard of careCOVID 19 outpatients, COVID-19 mild to moderateNA
    28/7 suggested
    • suggested 714.0-fold increase in viral clearance

    PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
    Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).